WO2002057437A3 - Generation of human cytomegalovirus yeast artificial chromosome recombinants - Google Patents

Generation of human cytomegalovirus yeast artificial chromosome recombinants Download PDF

Info

Publication number
WO2002057437A3
WO2002057437A3 PCT/US2001/047943 US0147943W WO02057437A3 WO 2002057437 A3 WO2002057437 A3 WO 2002057437A3 US 0147943 W US0147943 W US 0147943W WO 02057437 A3 WO02057437 A3 WO 02057437A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinants
generation
artificial chromosome
human cytomegalovirus
yeast artificial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/047943
Other languages
French (fr)
Other versions
WO2002057437A2 (en
Inventor
Peter Ghazal
Huang Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to AU2002246634A priority Critical patent/AU2002246634A1/en
Priority to DE60117053T priority patent/DE60117053T2/en
Priority to EP01994211A priority patent/EP1356062B1/en
Priority to HK03107960.8A priority patent/HK1055762B/en
Publication of WO2002057437A2 publication Critical patent/WO2002057437A2/en
Anticipated expiration legal-status Critical
Publication of WO2002057437A3 publication Critical patent/WO2002057437A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/206—Pseudochromosomes, minichrosomosomes of yeast origin, e.g. YAC, 2u
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a recombinant DNA construct comprising a YAC vector and at least a portion of the HCMV genome. The vector is useful as a basic research tool with which to study CMV biology, or as a vaccine with which to immunize a mammalian host against infection by CMV.
PCT/US2001/047943 2000-11-03 2001-10-30 Generation of human cytomegalovirus yeast artificial chromosome recombinants Ceased WO2002057437A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002246634A AU2002246634A1 (en) 2000-11-03 2001-10-30 Generation of human cytomegalovirus yeast artificial chromosome recombinants
DE60117053T DE60117053T2 (en) 2000-11-03 2001-10-30 PREPARATION OF RECOMBINANT ARTIFICIAL YEAST CHROMOSOME CONTAINING THE GENOME OF HUMAN CYTOMEGALOVIRUS
EP01994211A EP1356062B1 (en) 2000-11-03 2001-10-30 Generation of human cytomegalovirus yeast artificial chromosome recombinants
HK03107960.8A HK1055762B (en) 2000-11-03 2001-10-30 Generation of human cytomegalovirus yeast artificial chromosome recombinants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/705,400 US6692954B1 (en) 2000-11-03 2000-11-03 Generation of human cytomegalovirus yeast artificial chromosome recombinants
US09/705,400 2000-11-03

Publications (2)

Publication Number Publication Date
WO2002057437A2 WO2002057437A2 (en) 2002-07-25
WO2002057437A3 true WO2002057437A3 (en) 2003-08-14

Family

ID=24833288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047943 Ceased WO2002057437A2 (en) 2000-11-03 2001-10-30 Generation of human cytomegalovirus yeast artificial chromosome recombinants

Country Status (8)

Country Link
US (1) US6692954B1 (en)
EP (1) EP1356062B1 (en)
AT (1) ATE317016T1 (en)
AU (1) AU2002246634A1 (en)
DE (1) DE60117053T2 (en)
DK (1) DK1356062T3 (en)
ES (1) ES2255583T3 (en)
WO (1) WO2002057437A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790867B2 (en) * 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
DE602004025509D1 (en) 2003-11-28 2010-03-25 Univ Sydney VIRAL LATENT PHASE INTERLEUKIN-10- (VII-10) AND USES THEREOF
US8088902B2 (en) * 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
NZ554824A (en) 2004-10-22 2010-10-29 Revivicor Inc Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
US9267132B2 (en) 2007-10-08 2016-02-23 Synthetic Genomics, Inc. Methods for cloning and manipulating genomes
EP2348827B1 (en) 2008-10-27 2015-07-01 Revivicor, Inc. Immunocompromised ungulates
SG10201400436PA (en) 2009-03-06 2014-06-27 Synthetic Genomics Inc Methods For Cloning And Manipulating Genomes
EP2542676A1 (en) 2010-03-05 2013-01-09 Synthetic Genomics, Inc. Methods for cloning and manipulating genomes
EP2890787B1 (en) 2012-08-31 2019-05-01 Synthetic Genomics, Inc. Crowding agent-induced nucleic acid transfer into a recipient host cell
CA2890061A1 (en) * 2012-12-04 2014-06-12 Merck Sharp & Dohme Corp. Conditional replicating viral vectors
EP3049092A4 (en) * 2013-09-24 2017-09-06 Duke University Compositions, methods and kits for eliciting an immune response
WO2016168741A2 (en) * 2015-04-16 2016-10-20 Spencer Juliet V Detection of human cytomegalovirus
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
WO1999006582A1 (en) * 1997-08-01 1999-02-11 Koszinowski Ulrich H Recombinant vector containing infectious, viral genome sequences greater than 100 kb, method for producing same and use for the mutagenesis of the viral sequences
WO1999043842A1 (en) * 1998-02-26 1999-09-02 Neurovir, Inc. Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5721354A (en) 1995-03-31 1998-02-24 Aviron Human cytomegalovirus DNA sequences

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
WO1999006582A1 (en) * 1997-08-01 1999-02-11 Koszinowski Ulrich H Recombinant vector containing infectious, viral genome sequences greater than 100 kb, method for producing same and use for the mutagenesis of the viral sequences
WO1999043842A1 (en) * 1998-02-26 1999-09-02 Neurovir, Inc. Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GARCIA-RAMIREZ JOSE J ET AL: "Dominance of virus over host factors in cross-species activation of human cytomegalovirus early gene expression.", JOURNAL OF VIROLOGY, vol. 75, no. 1, January 2001 (2001-01-01), pages 26 - 35, XP002230079, ISSN: 0022-538X *
HORSBURGH B C ET AL: "ALLEL REPLACEMENT: AN APPLICATION THAT PERMITS RAPID MANIPULATION OF HERPES SIMPLEX VIRUS TYPE 1 GENOMES", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 5, May 1999 (1999-05-01), pages 922 - 930, XP001098376, ISSN: 0969-7128 *
KEMBLE GEORGE ET AL: "Defined large-scale alteration of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids.", JOURNAL OF VIROLOGY, vol. 70, no. 3, 1996, pages 2044 - 2048, XP002230078, ISSN: 0022-538X *
KETNER G ET AL: "Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 91, 1 June 1994 (1994-06-01), pages 6186 - 6190, XP002086654, ISSN: 0027-8424 *
MESSERLE ET AL: "CLONING AND MUTAGENESIS OF A HERPESVIRUS GENOME AS AN INFECTIOUS BACTERIAL ARTIFICIAL CHROMOSOME", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, December 1997 (1997-12-01), pages 14759 - 14763, XP002104658, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US6692954B1 (en) 2004-02-17
WO2002057437A2 (en) 2002-07-25
EP1356062A2 (en) 2003-10-29
DK1356062T3 (en) 2006-05-15
AU2002246634A1 (en) 2002-07-30
EP1356062B1 (en) 2006-02-01
ATE317016T1 (en) 2006-02-15
ES2255583T3 (en) 2006-07-01
HK1055762A1 (en) 2004-01-21
DE60117053T2 (en) 2006-08-17
DE60117053D1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
WO2002057437A3 (en) Generation of human cytomegalovirus yeast artificial chromosome recombinants
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
WO2000053729A3 (en) Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
WO2005012545A3 (en) Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
WO2001039797A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
EP2336370A3 (en) Recombinant Newcastle disease virus RNA expression systems and vaccines
DE69737886D1 (en) INFECTIOUSE RNA VIRUS CLONE, VACCINE, AND THEREFORE DERIVED DIAGNOSTIC ASSAYS
CY1106883T1 (en) Recombinant EVOLOGY VIRUS CONTAINING TWO MOVEMENTS AGAINST EVOLOGY ANGEL.
CA2193365A1 (en) Polynucleotide vaccine for papillomavirus
WO2003082183A3 (en) Protein-based streptococcus pneumoniae vaccines
JP2004509627A5 (en)
WO2003047617A3 (en) Vaccine
IL145797A0 (en) Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
CA2215328A1 (en) Novel human cytomegalovirus dna sequences
WO2002068654A3 (en) Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
UA84667C2 (en) Vaccine directed against infection induced by herpes virus of marek's disease
AU2003255315A1 (en) Vaccinia virus host range genes to increase the titer of avipoxviruses
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
WO2002092786A3 (en) A helper dependent adenoviral vector system and methods for using the same
ATE412762T1 (en) VECTOR FOR INTEGRATION OF HETEROLOGUESE SEQUENCES INTO POXVIRUS GENOMES
AU2002352195A1 (en) Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors
WO2004024756A3 (en) Orthopoxvirus antigens and use thereof
WO2004067032A3 (en) Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001994211

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001994211

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001994211

Country of ref document: EP